Aprea Therapeutics Q2 net loss widens on higher R&D costs

Aprea Therapeutics

12/08/2026 13:39

Overview
US oncology drug developer reported Q2 net loss widened to $3.6 mln, or $0.07 per share
Cash and equivalents rose to $41.2 mln, boosted by $30 mln private placement
R&D expenses increased as company advanced Phase 1 APR-1051 trial and expanded enrollment

Outlook
Aprea expects to report next APR-1051 clinical data update in Q4 2026
Company anticipates completing APR-1051 dose escalation and expansion in Q2 2027
Aprea expects cash and equivalents to fund operations into Q1 2028

Result Drivers
R&D EXPENSES - Higher R&D costs driven by expanded enrollment and dose escalation in Phase 1 APR-1051 trial
TRIAL EXPANSION - Accelerated enrollment and increase in active clinical sites for ACESOT-1051 trial
EARLY CLINICAL ACTIVITY - Early signs of activity for APR-1051, including partial responses and disease stabilization, prompted further trial expansion

Company press release: ID:nGNX4Bn51r

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.07
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Aprea Therapeutics Inc is $5.00, about 657.5% above its August 11 closing price of $0.66

Reuters Recommended Reads
Aug 11 - Oncology firm Immunome's Q2 net loss widens as R&D costs rise
Aug 11 - Intensity Therapeutics Q2 net loss widens as R&D costs rise
Aug 11 - Cardiff Oncology Q2 operating expenses fall on lower R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)